But biomarker enrichment and toxicity remain key for FX-909.
ApexOnco Front Page
Recent articles
The month saw the first commissioner's priority voucher approval in oncology.
The company's partner MediLink will start a pivotal trial of beruzatatug pelitecan in lung cancer.
After several discontinuations, a new ADC enters the clinic.
Hutchmed goes pivotal with HMPL-760 in B-cell lymphoma.
Median PFS appears to back earlier response rate promise.
The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
Solstice Oncology acquires porustobart from Harbour Biomed.
